Roland B Walter

List of Publications by Citations

302 papers	9,808 citations	49 h-index	90 g-index
330 ext. papers	11,899 ext. citations	4.9 avg, IF	6.32 L-index

#	Paper	IF	Citations
302	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. *Blood*, **2018**, 131, 1275-1291	2.2	528
301	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. *Blood*, **2013**, 121, 4854-60	2.2	441
300	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. *Journal of Clinical Oncology*, **2019**, 37, 1277-1284	2.2	320
299	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. *Blood*, **2013**, 122, 1455-63	2.2	313
298	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. *Journal of Clinical Oncology*, **2016**, 34, 329-36	2.2	270
297	Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. *Journal of Clinical Oncology*, **2011**, 29, 1190-7	2.2	270
296	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. *Blood*, **2013**, 122, 1813-21	2.2	264
295	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. *Journal of Clinical Oncology*, **2011**, 29, 4417-23	2.2	230
294	CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. *Blood*, **2013**, 122, 1316-24	2.2	218
293	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. *Blood*, **2012**, 119, 6198-208	2.2	217
292	Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. *Journal of Clinical Oncology*, **2015**, 33, 1258-64	2.2	163
291	CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. *Blood*, **2007**, 109, 4168-70	2.2	150
290	Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. *Journal of Clinical Oncology*, **2010**, 28, 1766-71	2.2	145
289	Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. *Leukemia*, **2015**, 29, 137-44	10.7	142
288	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. *Haematologica*, **2017**, 102, 865-873	6.6	132
287	Measurable residual disease testing in acute myeloid leukaemia. *Leukemia*, **2017**, 31, 1482-1490	10.7	132
286	Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. *Blood*, **2014**, 123, 554-61	2.2	132

285	Gemtuzumab ozogamicin in acute myeloid leukemia. *Leukemia*, **2017**, 31, 1855-1868	10.7	128
284	Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. *Blood*, **2005**, 105, 1295-302	2.2	127
283	Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. *Blood*, **2003**, 102, 1466-73	2.2	109
282	Pre- and post-transplant quantification of measurable (minimal) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. *Leukemia*, **2016**, 30, 1456-64	10.7	107
281	The past and future of CD33 as therapeutic target in acute myeloid leukemia. *Blood Reviews*, **2014**, 28, 143-53	11.1	107
280	Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. *Leukemia*, **2015**, 29, 312-20	10.7	106
279	Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. *Clinical Infectious Diseases*, **2003**, 36, 943-51	11.6	99
278	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. *Blood*, **2018**, 131, 387-396	2.2	95
277	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. *Journal of Clinical Oncology*, **2017**, 35, 2674-2682	2.2	93
276	Evaluating measurable residual disease in acute myeloid leukemia. *Blood Advances*, **2018**, 2, 1356-1366	7.8	87
275	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. *Cancer*, **2016**, 122, 1871-9	6.4	86
274	Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. *Leukemia*, **2010**, 24, 1276-82	10.7	81
273	Cutaneous graft-versus-host disease: a guide for the dermatologist. *Dermatology*, **2008**, 216, 287-304	4.4	81
272	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood*, **2021**, 137, 751-762	2.2	77
271	The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. *Blood*, **2004**, 103, 4276-84	2.2	76
270	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*, **2013**, 121, 2424-31	2.2	75
269	Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. *Blood*, **2012**, 119, 3705-11	2.2	75
268	Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. *Bone Marrow Transplantation*, **2013**, 48, 630-41	4.4	74

267	Management of older or unfit patients with acute myeloid leukemia. *Leukemia*, **2015**, 29, 770-5	10.7	72
266	Reactivation of herpesvirus infections after vaccinations?. *Lancet, The*, **1999**, 353, 810	40	71
265	Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia. *Molecular Cancer Therapeutics*, **2018**, 17, 554-564	6.1	64
264	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. *Blood*, **2010**, 116, 2420-8	2.2	62
263	Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. *Clinical Cancer Research*, **2016**, 22, 5829-5838	12.9	62
262	Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. *Annals of Hematology*, **2003**, 82, 570-3	3	59
261	Gemcitabine-associated hemolytic-uremic syndrome. *American Journal of Kidney Diseases*, **2002**, 40, E16	7.4	58
260	Rapid detection of pathogenic fungi from clinical specimens using LightCycler real-time fluorescence PCR. *European Journal of Clinical Microbiology and Infectious Diseases*, **2003**, 22, 558-60	5.3	58
259	Targeting MCL-1 in hematologic malignancies: Rationale and progress. *Blood Reviews*, **2020**, 44, 100672	11.1	57
258	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2020**, 6, 1890-1899	13.4	57
257	Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. *Clinical Cancer Research*, **2014**, 20, 2226-35	12.9	56
256	ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. *Journal of Leukocyte Biology*, **2008**, 83, 200-11	6.5	52
255	Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. *Blood*, **2014**, 123, 2960-7	2.2	51
254	Investigational CD33-targeted therapeutics for acute myeloid leukemia. *Expert Opinion on Investigational Drugs*, **2018**, 27, 339-348	5.9	49
253	Effects of high-altitude exposure on vascular endothelial growth factor levels in man. *European Journal of Applied Physiology*, **2001**, 85, 113-7	3.4	48
252	PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. *Blood*, **2005**, 106, 3584-93	2.2	47
251	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. *Frontiers in Bioscience - Landmark*, **2013**, 18, 1311-34	2.8	46
250	Height as an explanatory factor for sex differences in human cancer. *Journal of the National Cancer Institute*, **2013**, 105, 860-8	9.7	45

249	Effect of measurable (minimal) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. *Leukemia*, **2016**, 30, 2080-2083	10.7	45
248	T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. *Blood Cancer Journal*, **2015**, 5, e340	7	44
247	Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative. *International Journal of Cancer*, **2014**, 135, 1869-83	7.5	44
246	Differential regulation of constitutive and inducible nitric oxide production by inflammatory stimuli in murine endothelial cells. *Biochemical and Biophysical Research Communications*, **1994**, 202, 450-5	3.4	44
245	Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 559-64	4.7	42
244	Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. *JAMA Oncology*, **2017**, 3, 374-381	13.4	42
243	Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. *Leukemia*, **2015**, 29, 2104-7	10.7	41
242	Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. *Clinical Cancer Research*, **2013**, 19, 1620-7	12.9	41
241	Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. *Journal of Clinical Oncology*, **2011**, 29, 2424-31	2.2	41
240	A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). *Blood*, **2018**, 132, 25-25	2.2	41
239	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematology,the*, **2020**, 7, e601-e612	14.6	41
238	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. *Blood*, **2018**, 132, 1125-1133	2.2	40
237	First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα/ Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. *Blood*, **2014**, 124, 120-120	2.2	40
236	Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. *Haematologica*, **2014**, 99, 54-9	6.6	39
235	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia. *Blood*, **2016**, 128, 102-102	2.2	39
234	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. *Blood*, **2017**, 130, 890-890	2.2	39
233	Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. *Leukemia*, **2018**, 32, 1239-1243	10.7	38
232	Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia. *Blood*, **2003**, 101, 3755-6	2.2	38

231	The nitric oxide synthase cofactor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after lung transplantation. *Journal of Thoracic and Cardiovascular Surgery*, **1999**, 118, 726-32	1.5	38
230	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. *Blood*, **2015**, 126, 2790-7	2.2	37
229	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. *Blood*, **2016**, 128, 763-73	2.2	37
228	Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. *American Journal of Hematology*, **2014**, 89, 423-8	7.1	36
227	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1071-1071	2.2	36
226	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. *Journal of Clinical Oncology*, **2013**, 31, 3883-8	2.2	35
225	The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. *PLoS ONE*, **2015**, 10, e0135945	3.7	35
224	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis. *JAMA Oncology*, **2015**, 1, 1120-7	13.4	33
223	Minimal residual disease-directed therapy in acute myeloid leukemia. *Blood*, **2015**, 125, 2331-5	2.2	33
222	2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. *Blood*, **2021**,	2.2	33
221	Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. *Blood*, **2017**, 129, 2330-2332	2.2	31
220	High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. *Journal of Clinical Oncology*, **2010**, 28, 2831-8	2.2	31
219	Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. *Oncotarget*, **2016**, 7, 43281-43294	3.3	31
218	AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. *PLoS ONE*, **2013**, 8, e53518	3.7	30
217	Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 591-591	2.2	30
216	Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations. *Leukemia Research*, **2016**, 45, 53-8	2.7	30
215	Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. *Leukemia*, **2017**, 31, 2347-2354	10.7	28
214	Patient-reported outcomes in acute myeloid leukemia: Where are we now?. *Blood Reviews*, **2018**, 32, 81-87	11.1	28

213	High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *Journal of Hematology and Oncology*, **2015**, 8, 115	22.4	28
212	Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. *Haematologica*, **2011**, 96, 914-7	6.6	27
211	Pretargeted radioimmunotherapy for hematologic and other malignancies. *Cancer Biotherapy and Radiopharmaceuticals*, **2010**, 25, 125-42	3.9	27
210	Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage. *Journal of Leukocyte Biology*, **2006**, 79, 312-8	6.5	27
209	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. *Clinical Advances in Hematology and Oncology*, **2013**, 11, 571-7	0.6	27
208	Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. *Traffic*, **2008**, 9, 267-79	5.7	26
207	Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. *Blood*, **2018**, 132, 284-284	2.2	26
206	Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. *Leukemia*, **2014**, 28, 713-6	10.7	25
205	A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 324-324	2.2	25
204	Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. *PLoS ONE*, **2011**, 6, e24265	3.7	25
203	Minimal residual disease in acute myeloid leukemia--current status and future perspectives. *Current Hematologic Malignancy Reports*, **2015**, 10, 132-44	4.4	24
202	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. *Haematologica*, **2012**, 97, 739-42	6.6	24
201	Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 623-623	2.2	24
200	Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. *Blood Reviews*, **2019**, 34, 26-33	11.1	24
199	Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. *Leukemia*, **2019**, 33, 762-808	10.7	24
198	Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2298-308	4	23
197	Commercial taxane formulations induce stomatocytosis and increase blood viscosity. *British Journal of Pharmacology*, **2001**, 134, 1207-14	8.6	23
196	Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. *Leukemia*, **2017**, 31, 2560-2567	10.7	22

195	Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. *Journal of Thrombosis and Thrombolysis*, **2017**, 44, 442-447	5.1	22
194	Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. *British Journal of Haematology*, **2016**, 172, 238-45	4.5	22
193	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. *Leukemia*, **2018**, 32, 2352-2362	10.7	21
192	HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 1314-9	5.9	21
191	Bone marrow involvement in Whipple disease: rarely reported, but really rare?. *British Journal of Haematology*, **2001**, 112, 677-9	4.5	21
190	A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 211-211	2.2	21
189	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1615-1620	4.7	20
188	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. *Leukemia Research*, **2014**, 38, 329-33	2.7	20
187	Functional tetrahydrobiopterin synthesis in human platelets. *Circulation*, **2004**, 110, 186-92	16.7	20
186	Quality of life from the perspective of the patient with acute myeloid leukemia. *Cancer*, **2018**, 124, 145-152	6.4	19
185	Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?. *Expert Review of Hematology*, **2016**, 9, 335-50	2.8	19
184	Antigen-specific immunotherapies for acute myeloid leukemia. *Hematology American Society of Hematology Education Program*, **2015**, 2015, 584-95	3.1	19
183	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥65 with acute myelogenous leukemia.. *Journal of Clinical Oncology*, **2016**, 34, 7007-7007	2.2	19
182	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. *Haematologica*, **2018**, 103, e106-e109	6.6	18
181	Critical role of interleukin-1beta for transcriptional regulation of endothelial 6-pyruvoyltetrahydropterin synthase. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, e50-3	9.4	18
180	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). *Blood*, **2016**, 128, 215-215	2.2	18
179	Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 590-590	2.2	18
178	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 373-8	4.7	17

177	Acidosis induced by lactate, pyruvate, or HCl increases blood viscosity. *Journal of Critical Care*, **2002**, 17, 68-73	4	17
176	G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. *American Journal of Hematology*, **2015**, 90, 295-300	7.1	15
175	SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. *Blood*, **2015**, 126, 454-454	2.2	15
174	Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. *Leukemia*, **2021**, 35, 1529-1538	10.7	15
173	The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia. *Current Hematologic Malignancy Reports*, **2017**, 12, 547-556	4.4	14
172	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. *Leukemia Research*, **2020**, 95, 106385	2.7	14
171	High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children© Oncology Group. *Leukemia and Lymphoma*, **2014**, 55, 2817-21	1.9	14
170	Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. *Intensive Care Medicine*, **2003**, 29, 337	14.5	14
169	Primary pleomorphic adenoma of the external auditory canal diagnosed by fine needle aspiration cytology. A case report. *Acta Cytologica*, **1999**, 43, 489-91	3	14
168	SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML. *Blood*, **2015**, 126, 330-330	2.2	14
167	Associations between allergies and risk of hematologic malignancies: results from the VITamins and lifestyle cohort study. *American Journal of Hematology*, **2013**, 88, 1050-4	7.1	13
166	Untroubled musical judgement of a performing organist during early epileptic seizure of the right temporal lobe. *Neuropsychologia*, **1997**, 35, 45-51	3.2	13
165	Induction of tetrahydrobiopterin synthesis in human umbilical vein smooth muscle cells by inflammatory stimuli. *Immunology Letters*, **1998**, 60, 13-7	4.1	13
164	Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. *Blood*, **2008**, 111, 4813-6	2.2	13
163	Fatal necrotizing fasciitis due to Streptococcus pneumoniae after renal transplantation. *Nephrology Dialysis Transplantation*, **2003**, 18, 195-7	4.3	13
162	Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult. *Annals of Hematology*, **2002**, 81, 672-5	3	13
161	Update on antigen-specific immunotherapy of acute myeloid leukemia. *Current Hematologic Malignancy Reports*, **2015**, 10, 65-75	4.4	12
160	The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy. *Blood Cancer Journal*, **2015**, 5, e276	7	12

159	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. *Blood Reviews*, **2020**, 44, 100679	11.1	12
158	Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study. *Annals of Oncology*, **2013**, 24, 1370-7	10.3	12
157	Metastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels. *Experimental Hematology*, **2002**, 30, 1-2	3.1	12
156	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. *Cancers*, **2020**, 12,	6.6	12
155	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. *Current Hematologic Malignancy Reports*, **2019**, 14, 171-178	4.4	11
154	Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 865-882	4	11
153	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). *Journal of Drug Assessment*, **2018**, 7, 51-53	1.5	11
152	Influence of nitrovasodilators and endothelin-1 on rheology of human blood in vitro. *British Journal of Pharmacology*, **1999**, 128, 744-50	8.6	11
151	Novel monoclonal antibody-based therapies for acute myeloid leukemia. *Best Practice and Research in Clinical Haematology*, **2019**, 32, 116-126	4.2	10
150	Outpatient induction and consolidation care strategies in acute myeloid leukemia. *Current Opinion in Hematology*, **2019**, 26, 65-70	3.3	10
149	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. *Leukemia*, **2020**, 34, 1577-1587	10.7	10
148	Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. *Leukemia Research*, **2014**, 38, 564-8	2.7	10
147	Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?. *Leukemia*, **2017**, 31, 2536-2537	10.7	10
146	Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study. *Leukemia and Lymphoma*, **2013**, 54, 2534-6	1.9	10
145	Cancer risk associated with long-term use of acetaminophen in the prospective VITamins and lifestyle (VITAL) study. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2637-41	4	10
144	Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells. *Leukemia*, **2004**, 18, 1914-7	10.7	10
143	Pharmacological concentrations of arginine influence human whole blood viscosity independent of nitric oxide synthase activity in vitro. *Biochemical and Biophysical Research Communications*, **2000**, 269, 687-91	3.4	10
142	Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.. *Journal of Clinical Oncology*, **2011**, 29, 6506-6506	2.2	10

141	Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. *Journal of Clinical Oncology*, **2020**, 38, 4163-4174	2.2	10
140	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood Advances*, **2020**, 4, 611-616	7.8	10
139	Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?. *Current Opinion in Hematology*, **2017**, 24, 132-138	3.3	9
138	Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children Oncology Group. *Clinical Cancer Research*, **2015**, 21, 3187-95	12.9	9
137	Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. *Leukemia*, **2014**, 28, 1969-77	10.7	9
136	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. *Haematologica*, **2015**, 100, e409-11	6.6	9
135	Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co-Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML. *Blood*, **2018**, 132, 1436-1436	2.2	9
134	Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. *Haematologica*, **2019**, 104, e143-e146	6.6	9
133	Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. *Blood*, **2021**, 137, 569-572	2.2	9
132	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E49-E52	7.1	9
131	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. *Haematologica*, **2015**, 100, e97-8	6.6	8
130	Fatal hepatic veno-occlusive disease associated with terbinafine in a liver transplant recipient. *Journal of Hepatology*, **2003**, 38, 373-4	13.4	8
129	Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment. *Blood*, **2010**, 116, 2191-2191	2.2	8
128	COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia. *Leukemia*, **2019**, 33, 805-808	10.7	8
127	Relationship between CD33 expression, splicing polymorphism, and cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE AMG 330. *Haematologica*, **2019**, 104, e59-e62	6.6	8
126	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after Day 14 without further therapy in acute myeloid leukemia. *Leukemia and Lymphoma*, **2017**, 58, 2717-2719	1.9	7
125	A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. *British Journal of Haematology*, **2015**, 170, 349-55	4.5	7
124	Myeloid sarcoma of the heart. *Leukemia and Lymphoma*, **2012**, 53, 2511-4	1.9	7

123	Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). *British Journal of Haematology*, **2000**, 109, 396-404	4.5	7
122	Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 3819-3819	2.2	7
121	Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. *Leukemia and Lymphoma*, **2020**, 61, 1158-1167	1.9	7
120	The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. *Leukemia*, **2020**, 34, 2479-2483	10.7	6
119	Incorporating measurable (minimal) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. *Leukemia and Lymphoma*, **2016**, 57, 1527-33	1.9	6
118	Prediction of early death in adults with relapsed or refractory acute myeloid leukemia. *Leukemia and Lymphoma*, **2016**, 57, 2421-4	1.9	6
117	Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. *American Journal of Hematology*, **2013**, 88, 694-702	7.1	6
116	Inhalation of the nitric oxide synthase cofactor tetrahydrobiopterin in healthy volunteers. *American Journal of Respiratory and Critical Care Medicine*, **1997**, 156, 2006-10	10.2	6
115	Influence of parathyroid hormone, calcitonin, 1,25(OH)2 cholecalciferol, calcium, and the calcium ionophore A23187 on erythrocyte morphology and blood viscosity. *Translational Research*, **2000**, 135, 347-52		6
114	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. *Leukemia*, **2019**, 33, 554-558	10.7	6
113	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. *Leukemia*, **2020**, 34, 635-639	10.7	6
112	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. *British Journal of Haematology*, **2016**, 172, 134-6	4.5	5
111	Low platelet count reduces subsequent complete remission rate despite marrow with . *Leukemia*, **2015**, 29, 1779-80	10.7	5
110	Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient. *Bone Marrow Transplantation*, **2006**, 37, 109-10	4.4	5
109	Tetrahydrobiopterin in the vascular system. *Pteridines*, **2001**, 12, 93-120	0.6	5
108	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial.	2.2	5
107	SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML. *Blood*, **2012**, 120, 3589-3589	2.2	5
106	Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 129-134	3.1	5

105	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. *Blood*, **2021**, 138, 372-372	2.2	5
104	T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies. *Current Hematologic Malignancy Reports*, **2016**, 11, 311-7	4.4	5
103	Antibody-Based Therapeutics Targeting CD33, CD45, and CD66 **2015**, 531-555		4
102	SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML). *Biology of Blood and Marrow Transplantation*, **2016**, 22, S211-S212	4.7	4
101	High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children© Oncology Group. *Leukemia and Lymphoma*, **2013**, 54, 202-4	1.9	4
100	The power of comparative studies. *Leukemia Research*, **2009**, 33, 610-2	2.7	4
99	Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 648-54	5.9	4
98	Images in clinical medicine. Vitiligo and pernicious anemia. *New England Journal of Medicine*, **2004**, 350, 2698	59.2	4
97	Impairment of blood rheology by cholestatic jaundice in human beings. *Translational Research*, **2003**, 142, 391-8		4
96	Systemic tetrahydrobiopterin (BH4) levels and coronary artery disease. *Cardiology*, **2000**, 94, 265-6	1.6	4
95	A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 340-340	2.2	4
94	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. *Bone Marrow Transplantation*, **2020**, 55, 669-672	4.4	4
93	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. *Leukemia and Lymphoma*, **2019**, 60, 1023-1029	1.9	4
92	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. *British Journal of Haematology*, **2021**, 192, 832-842	4.5	4
91	Next-generation sequencing for measuring minimal residual disease in AML. *Nature Reviews Clinical Oncology*, **2018**, 15, 473-474	19.4	4
90	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. *Haematologica*, **2015**, 100, e254-6	6.6	3
89	Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. *Leukemia and Lymphoma*, **2015**, 56, 782-4	1.9	3
88	Mott cells. *European Journal of Haematology*, **2013**, 90, 83	3.8	3

87	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.. *Journal of Clinical Oncology*, **2017**, 35, 7016-7016	2.2	3
86	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. *Leukemia*, **2020**, 34, 1701-1705	10.7	3
85	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. *Haematologica*, **2021**, 106, 2114-2120	6.6	3
84	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.. *HemaSphere*, **2022**, 6, e676	0.3	3
83	Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms. *Leukemia and Lymphoma*, **2019**, 60, 2304-2307	1.9	2
82	Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). *Cancers*, **2020**, 12,	6.6	2
81	Near-fatal arrhythmia caused by hyperkalaemia. *British Heart Journal*, **2002**, 88, 578		2
80	Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. *Blood*, **2018**, 132, 1403-1403	2.2	2
79	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study. *Blood*, **2013**, 122, 3936-3936	2.2	2
78	Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2015**, 33, 7067-7067	2.2	2
77	A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.. *Journal of Clinical Oncology*, **2016**, 34, TPS7071-TPS7071	2.2	2
76	Determinants of quality of life in patients with acute myeloid leukemia.. *Journal of Clinical Oncology* , **2017**, 35, e18528-e18528	2.2	2
75	Acute Myeloid Leukemia **2011**, 2, 219-237		2
74	Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia. *Leukemia and Lymphoma*, **2020**, 61, 2990-2994	1.9	2
73	Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?. *Current Opinion in Hematology*, **2016**, 23, 102-7	3.3	2
72	Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia. *Pharmacoeconomics*, **2021**, 39, 121-131	4.4	2
71	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. *Leukemia and Lymphoma*, **2021**, 62, 234-238	1.9	2
70	Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection. *Transplantation and Cellular Therapy*, **2021**, 27, 684.e1-684.e9		2

69	The Bruton tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity. *British Journal of Haematology*, **2020**, 189, e9-e13	4.5	1
68	Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. *British Journal of Haematology*, **2014**, 166, 375-81	4.5	1
67	Letter regarding article by Vita et al, "serum myeloperoxidase levels independently predict endothelial dysfunction in humans". *Circulation*, **2005**, 111, e167-8; author reply e167-8	16.7	1
66	Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. *Blood*, **2018**, 132, 2710-2710	2.2	1
65	Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.. *Blood*, **2006**, 108, 2324-2324	2.2	1
64	The Broad Activity of the CD33/CD3 Bispecific BiTE Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk. *Blood*, **2014**, 124, 266-266	2.2	1
63	Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. *Blood*, **2014**, 124, 3732-3732	2.2	1
62	Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality. *Blood*, **2014**, 124, 994-994	2.2	1
61	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2569-2569	2.2	1
60	A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2016**, 128, 1068-1068	2.2	1
59	Development of Astatine-211 (211At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies. *Blood*, **2021**, 138, 3341-3341	2.2	1
58	Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 1-10	7.3	1
57	Need for routine examination of left ventricular ejection fraction in patients with AML. *Leukemia*, **2020**, 34, 1169-1171	10.7	1
56	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). *Leukemia and Lymphoma*, **2021**, 62, 1532-1535	1.9	1
55	Reply to C.S. Hourigan et al. *Journal of Clinical Oncology*, **2016**, 34, 2558-9	2.2	1
54	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. *Leukemia and Lymphoma*, **2016**, 57, 1205-7	1.9	1
53	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. *Bone Marrow Transplantation*, **2019**, 54, 1511-1514	4.4	1
52	Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. *Leukemia*, **2021**, 35, 295-298	10.7	1

51	Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy. *Leukemia*, **2021**, 35, 2496-2507	10.7	1
50	Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. *Leukemia and Lymphoma*, **2020**, 61, 1728-1731	1.9	0
49	Reply to F. Ferrara. *Journal of Clinical Oncology*, **2012**, 30, 463-464	2.2	0
48	Comparative analysis of infectious complications with outpatient inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. *Leukemia and Lymphoma*, **2021**, 1-10	1.9	0
47	Where do we stand with radioimmunotherapy for acute myeloid leukemia?. *Expert Opinion on Biological Therapy*, **2022**, 1-7	5.4	0
46	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation.. *American Journal of Hematology*, **2022**,	7.1	0
45	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e633-e635	2	
44	In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia. *Clinical Infectious Diseases*, **2019**, 68, 525-529	11.6	
43	How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1340-2	4.7	
42	Chronic myeloid leukemia in lymphoid blast crisis. *European Journal of Haematology*, **2014**, 92, 458	3.8	
41	A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. *British Journal of Haematology*, **2013**, 163, 130-2	4.5	
40	Acute severe anaemia in an elderly patient with hereditary sphaerocytosis. *Postgraduate Medical Journal*, **2003**, 79, 244, 246	2	
39	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 12-13	2.2	
38	Selection of Patients for Individual Acute Myeloid Leukemia Therapies. *Hematologic Malignancies*, **2021**, 69-75	0	
37	Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946-October 8, 2021). *Leukemia*, **2021**, 35, 3619-3621	10.7	
36	Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy. *Blood*, **2021**, 138, 2776-2776	2.2	
35	Validation of the AML-QOL: A Quality of Life Instrument for Patients with Acute Myeloid Leukemia and Other Aggressive Myeloid Neoplasms. *Blood*, **2018**, 132, 4822-4822	2.2	
34	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. *Blood*, **2018**, 132, 5255-5255	2.2	

33	Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2. *Blood*, **2018**, 132, 2200-2200	2.2
32	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. *Blood*, **2018**, 132, 3978-3978	2.2
31	Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia. *Blood*, **2019**, 134, 2561-2561	2.2
30	Correlation between peripheral blood and bone marrow regarding FLT3 ITD and NPM1 mutational status in patients with AML.. *Journal of Clinical Oncology*, **2014**, 32, 7077-7077	2.2
29	A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. *Blood*, **2014**, 124, 3690-3690	2.2
28	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study. *Blood*, **2014**, 124, 3730-3730	2.2
27	Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. *Blood*, **2014**, 124, 5257-5257	2.2
26	Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia. *Blood*, **2014**, 124, 2277-2277	2.2
25	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. *Blood*, **2014**, 124, 3676-3676	2.2
24	The Treatment Related Mortality Score Predicts Early Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 2276-2276	2.2
23	Cell Signaling and Resistance to Immunotoxins. *Resistance To Targeted Anti-cancer Therapeutics*, **2015**, 75-87	0.3
22	Discrepancy in bone marrow blast counts between morphology and flow cytometry and its potential clinical implications.. *Journal of Clinical Oncology*, **2015**, 33, e18031-e18031	2.2
21	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. *Blood*, **2015**, 126, 2571-2571	2.2
20	High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children© Oncology Group. *Blood*, **2015**, 126, 2570-2570	2.2
19	Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study. *Blood*, **2015**, 126, 5635-5635	2.2
18	Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2015**, 126, 173-173	2.2
17	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 1339-1339	2.2
16	Prognostic implication of minimal residual disease in AML.. *Journal of Clinical Oncology*, **2016**, 34, 7016-7016	2.2

15	The Role of Notch in Vascular Endothelial Cell-Mediated Protection of AML Precursors from Targeted Therapy. *Blood*, **2016**, 128, 2750-2750	2.2
14	Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly AML or High Risk MDS Patients. *Blood*, **2016**, 128, 5207-5207	2.2
13	CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study. *Blood*, **2016**, 128, 2743-2743	2.2
12	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. *Blood*, **2016**, 128, 2792-2792	2.2
11	The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis. *Blood*, **2016**, 128, 2842-2842	2.2
10	A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2016**, 128, 4043-4043	2.2
9	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study. *Blood*, **2016**, 128, 1064-1064	2.2
8	Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).. *Blood*, **2010**, 116, 3806-3806	2.2
7	Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. *Blood*, **2011**, 118, 1446-1446	2.2
6	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2013**, 122, 303-303	2.2
5	Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML. *Blood*, **2013**, 122, 2932-2932	2.2
4	Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia. *Blood*, **2013**, 122, 1318-1318	2.2
3	Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. *Leukemia and Lymphoma*, **2021**, 62, 1774-1777	1.9
2	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. *Hemato*, **2021**, 2, 79-88	0.2
1	AML Debate: Use Gemtuzumab Ozogamicin in Most AML Patients vs. Use in CBF Patients or Not at All? Pro. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, S61-S63	2